Voyager Therapeutics, Inc. Stock-Based Compensation
Voyager Therapeutics, Inc. (VYGR) reported Stock-Based Compensation of $4.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Voyager Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.43M, a 41.13% decline year-over-year.
- Voyager Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.49M, a 32.26% decline year-over-year.
- Voyager Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.52M, a 5.78% decline year-over-year.
- Voyager Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.46M, a 0.79% increase year-over-year.
- Voyager Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $14.79M, a 0.01% increase from fiscal 2024.
- Voyager Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $14.79M, a 32.57% increase from fiscal 2023.
- Voyager Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $11.15M, a 19.36% increase from fiscal 2022.
- Voyager Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $9.34M, a 17.48% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.92M 10-Q · filed 2026-08-06 | $8.44M derived: sum of 3 quarters · filed 2026-08-06 | $11.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.49M 10-Q · filed 2026-05-07 | $6.01M derived: sum of 2 quarters · filed 2026-05-07 | $9.47M derived: sum of 3 quarters · filed 2026-05-07 | $13.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.98M derived: sum of 2 quarters · filed 2026-03-09 | $11.11M derived: sum of 3 quarters · filed 2026-08-06 | $14.79M 10-K · filed 2026-03-09 |
| 2025-09-30 | $3.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $7.59M derived: sum of 2 quarters · filed 2026-08-06 | $11.27M 10-Q · filed 2025-11-10 | $15.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.81M 10-Q · filed 2026-08-06 | $11.54M derived: sum of 3 quarters · filed 2026-08-06 | $14.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.67M 10-Q · filed 2026-05-07 | $7.41M derived: sum of 2 quarters · filed 2026-05-07 | $10.84M derived: sum of 3 quarters · filed 2026-05-07 | $14.88M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $7.17M derived: sum of 2 quarters · filed 2026-03-09 | $11.21M derived: sum of 3 quarters · filed 2026-03-09 | $14.79M 10-K · filed 2026-03-09 |
| 2024-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $7.47M derived: sum of 2 quarters · filed 2025-11-10 | $11.05M 10-Q · filed 2025-11-10 | $14.09M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $7.62M 10-Q · filed 2025-08-06 | $10.66M derived: sum of 3 quarters · filed 2026-03-09 | $13.54M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $3.57M 10-Q · filed 2025-05-06 | $6.62M derived: sum of 2 quarters · filed 2026-03-09 | $9.50M derived: sum of 3 quarters · filed 2026-03-09 | $12.17M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $5.92M derived: sum of 2 quarters · filed 2026-03-09 | $8.60M derived: sum of 3 quarters · filed 2026-03-09 | $11.15M 10-K · filed 2026-03-09 |
| 2023-09-30 | $2.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.55M derived: sum of 2 quarters · filed 2024-11-12 | $8.11M 10-Q · filed 2024-11-12 | $10.45M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $5.23M 10-Q · filed 2024-08-06 | $7.58M derived: sum of 3 quarters · filed 2025-03-11 | $9.77M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $2.56M 10-Q · filed 2024-05-13 | $4.90M derived: sum of 2 quarters · filed 2025-03-11 | $7.09M derived: sum of 3 quarters · filed 2025-03-11 | $9.58M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $4.54M derived: sum of 2 quarters · filed 2025-03-11 | $7.03M derived: sum of 3 quarters · filed 2025-03-11 | $9.34M 10-K · filed 2025-03-11 |
| 2022-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $4.68M derived: sum of 2 quarters · filed 2023-11-06 | $7.00M 10-Q · filed 2023-11-06 | $8.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.81M 10-Q · filed 2023-08-03 | $6.46M derived: sum of 3 quarters · filed 2024-02-28 | $8.54M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.32M 10-Q · filed 2023-05-09 | $3.97M derived: sum of 2 quarters · filed 2024-02-28 | $6.05M derived: sum of 3 quarters · filed 2024-02-28 | $10.04M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $3.73M derived: sum of 2 quarters · filed 2024-02-28 | $7.72M derived: sum of 3 quarters · filed 2024-02-28 | $11.32M 10-K · filed 2024-02-28 |
| 2021-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $6.07M derived: sum of 2 quarters · filed 2022-11-08 | $9.67M 10-Q · filed 2022-11-08 | $13.17M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $7.59M 10-Q · filed 2022-08-04 | $11.09M derived: sum of 3 quarters · filed 2023-03-07 | $14.63M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $3.60M 10-Q · filed 2022-05-04 | $7.10M derived: sum of 2 quarters · filed 2023-03-07 | $10.63M derived: sum of 3 quarters · filed 2023-03-07 | $14.49M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $7.03M derived: sum of 2 quarters · filed 2023-03-07 | $10.89M derived: sum of 3 quarters · filed 2023-03-07 | $14.93M 10-K · filed 2023-03-07 |
| 2020-09-30 | $3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $7.39M derived: sum of 2 quarters · filed 2021-11-02 | $11.43M 10-Q · filed 2021-11-02 | $14.95M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $3.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $7.90M 10-Q · filed 2021-08-09 | $11.42M derived: sum of 3 quarters · filed 2022-03-08 | $14.77M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $4.04M 10-Q · filed 2021-05-10 | $7.56M derived: sum of 2 quarters · filed 2022-03-08 | $10.91M derived: sum of 3 quarters · filed 2022-03-08 | $16.16M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $6.87M derived: sum of 2 quarters · filed 2022-03-08 | $12.12M derived: sum of 3 quarters · filed 2022-03-08 | $15.64M 10-K · filed 2022-03-08 |
| 2019-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $8.60M derived: sum of 2 quarters · filed 2020-11-09 | $12.12M 10-Q · filed 2020-11-09 | $14.76M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $5.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $8.77M 10-Q · filed 2020-08-10 | $11.41M derived: sum of 3 quarters · filed 2021-02-25 | $14.04M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $3.52M 10-Q · filed 2020-05-06 | $6.16M derived: sum of 2 quarters · filed 2021-02-25 | $8.79M derived: sum of 3 quarters · filed 2021-02-25 | $16.91M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $2.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.27M derived: sum of 2 quarters · filed 2021-02-25 | $13.39M derived: sum of 3 quarters · filed 2021-02-25 | $15.71M 10-K · filed 2021-02-25 |
| 2018-09-30 | $2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $10.75M derived: sum of 2 quarters · filed 2019-11-06 | $13.07M 10-Q · filed 2019-11-06 | $15.37M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $8.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $10.44M 10-Q · filed 2019-08-09 | $12.73M derived: sum of 3 quarters · filed 2020-03-03 | $15.97M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $2.32M 10-Q · filed 2019-05-07 | $4.62M derived: sum of 2 quarters · filed 2020-03-03 | $7.86M derived: sum of 3 quarters · filed 2020-03-03 | $9.39M derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $5.53M derived: sum of 2 quarters · filed 2020-03-03 | $7.07M derived: sum of 3 quarters · filed 2020-03-03 | $9.24M 10-K · filed 2020-03-03 |
| 2017-09-30 | $3.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $4.78M derived: sum of 2 quarters · filed 2018-11-07 | $6.95M 10-Q · filed 2018-11-07 | $8.73M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $3.70M 10-Q · filed 2018-08-07 | $5.49M derived: sum of 3 quarters · filed 2019-02-26 | $7.28M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $2.17M 10-Q · filed 2018-05-10 | $3.95M derived: sum of 2 quarters · filed 2019-02-26 | $5.74M derived: sum of 3 quarters · filed 2019-02-26 | $7.05M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $3.57M derived: sum of 2 quarters · filed 2019-02-26 | $4.89M derived: sum of 3 quarters · filed 2019-02-26 | $6.31M 10-K · filed 2019-02-26 |
| 2016-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $3.11M derived: sum of 2 quarters · filed 2017-11-02 | $4.53M 10-Q · filed 2017-11-02 | $6.49M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $2.74M 10-Q · filed 2017-08-08 | $4.71M derived: sum of 3 quarters · filed 2018-03-14 | $5.56M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $1.42M 10-Q · filed 2017-05-09 | $3.39M derived: sum of 2 quarters · filed 2018-03-14 | $4.25M derived: sum of 3 quarters · filed 2018-03-14 | $5.15M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $2.82M derived: sum of 2 quarters · filed 2018-03-14 | $3.73M derived: sum of 3 quarters · filed 2018-03-14 | $4.03M 10-K · filed 2018-03-14 |
| 2015-09-30 | $857.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.76M derived: sum of 2 quarters · filed 2016-11-10 | $2.06M 10-Q · filed 2016-11-10 | $2.21M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $902.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $1.20M 10-Q · filed 2016-08-11 | $1.35M derived: sum of 3 quarters · filed 2017-03-15 | |
| 2015-03-31 | $302.00K 10-Q · filed 2016-05-12 | $452.00K derived: sum of 2 quarters · filed 2017-03-15 | ||
| 2014-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $425.00K 10-K · filed 2017-03-15 | ||
| 2014-09-30 | $275.00K 10-Q · filed 2015-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |